Elanco Animal Health Inc

Elanco Animal Health: Driving growth in companion‑animal pain relief with innovative NSAID, opioid and combination therapies, positioning itself as a market leader in pet‑health solutions.

Elanco Animal Health Inc. has had a remarkable year, solidifying its position in the pharmaceutical sector, expanding its community engagement initiatives, and demonstrating strong financial performance.

Elanco Animal Health Inc. is a publicly traded company specializing in animal health products, with a global presence and a market capitalization of approximately $6.29 billion USD.

Elanco Animal Health Inc. reported strong Q1 2025 performance, with revenue growth and strategic moves, including a $295 million royalty sale, positioning the company for continued success in the animal health sector.

Elanco Animal Health Inc. reported Q1 2025 revenue of $1.193 billion, beating expectations and raising its 2025 revenue guidance to $4.51-$4.58 billion.

Elanco Animal Health Inc. reported strong Q1 2025 performance, with revenue growth and strategic moves positioning the company for sustained success in the animal health industry.

Elanco Animal Health Inc. reported a 1% decline in revenue for Q1 2025, but raised its full-year revenue guidance and announced a $295 million sale of royalties and milestones to Blackstone Inc.

Elanco Animal Health Inc. has sold certain royalties and commercial milestones to Blackstone for $295 million, a move aimed at strengthening its financial position and improving its leverage ratio.